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Abstract
The development of pharmaceuticals products is a complex and arduous process. It requires
significant investment (both financial and time). The costs of developing products range from
$314 million to $2.8 billion, with the time of bringing a new drug to market up to 15 years.
The overall probability of success from phase 1 to approval is estimated at between 9% to
12%. Concerns have been raised in the fall off of new approvals and the decreasing number
of innovative therapies coming through pharmaceutical R&D divisions. Academia is
recognised as a source of such new therapies, but their strengths do not lie in successfully
getting product to market. Difficulties arise in the academic setting, due to their lack of
understanding and knowledge of the rigorous regulatory requirements that are needed to
gain clearance to market pharmaceutical products. Additional tools are needed to aid
academic researchers navigate the necessary regulatory pathways. Whilst Technology
Readiness Level (TRL) tools exist, they are simplistic in nature and do not provide the
necessary detail to facilitate this process. An expansion of the TRL is proposed as one such
solution, in the form of a Regulatory Readiness (RRL) tool. This tool will serve as a suitable
method to ensure academics have the knowledge and skills to incorporate regulatory science
into their product development processes.

Introduction
The development of products in the life science sector (Pharmaceutical and Med Tech) is
multifaceted and complex, with inherent risk that a product in development will not succeed,
even after very substantial financial and time investment (Zurdo, 2013; DiMasi, 2016; Eilat,
2018). Data shows that in the United States the overall success rates from Phase 1stage to a
successful US FDA approval is roughly 9-13% (Hay, 2014; Thomas, 2016; FDA, 2017; Takabe,
2018; Wong 2019). The challenges related to drug development include scientific, technical,
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and regulatory issues and as the industry has developed over the years, the complexities of
development have increased, with the results that companies are channelling their Research
and Development (R&D) into areas such as Biopharmaceuticals and Advanced Therapeutic
Medicines, with associated high failure risks (PhRMA, 2015). This has added to increasing
timelines to take products from initial inception to the market. Drug development costs have
steadily increased since the 1950s; with a doubling of costs approximately every 9 years
(Scannell, 2012). In the recent years there has been an increase in expenditures on research
whilst the number of compounds in late-stage development has declined. The time to bring
a new drug to market ranges from 10 – 15 years with estimates of the cost to bring a new
drug to market vary with figures of $314 million - $2.8 billion being calculated (DiMasi, 2016;
Takabe, 2018). Woulter et al (Woulter, 2020) put this cost per product at $985 million,
counting expenditures on failed trials. Late-stage failures remain a major cost in any drug
development programme (Yildirim, 2016). In research millions of molecules are tested,
thousands are selected and moved to development where most fail to progress in preclinical
or clinical settings (Shannon, 2007; Mohs, 2017; Toriesen, 2015). The progression of novel
therapeutics from the laboratory to the clinic is poor, with a success rate of less than 10%,
with safety and poor efficacy cited as the main causes of attrition (Yildirim, 2016; Lowe, 2019).
The number of compounds being brought from development to successful launch decreases
as they progresses though the clinical development phases, with the likelihood that for every
10,000 compounds identified at the pre-clinical evaluation stage only one succeeds to market
approval. Until recently it was quoted that once in the clinical phase there is approximately a
20% success rate from the start of the clinical trials to marketing approval (DiMasi, 2016;
Wong 2019) but Woulter et al (Woulter, 2020) reviewed the aggregate success rates across a
number of studies and reported the overall probability of clinical success (the success rates
for a drug entering clinical testing to approval) is estimated to be between 9% -12%. Data
presented in 2019 from the Centre for Medicines Research (CMR) International, consortium
(Dowden, 2019) indicate success rates in the later stages of development improve with a 66%
chance of progression from phase III through to launch whilst for drug candidates in phase II
the probability of successfully progressing to phase III is approximately 25%. Paul et al (Paul,
2010) estimate that to yield a single New Molecular Entity (NME) launch per annum, then at
least 9 molecules must enter clinical development every year. As most large companies aspire
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for 2–5 launches per year approximately 18–45 Phase I starts would be required annually to
generate this rate of progression based on previous experience.
Regardless of the exact proportion of compounds finally achieving launch at a commercial
level, the process has rightly been described as a “leaky sieve”. Indeed if one is to bench mark
the healthcare industry success rates against other industries for given the levels of
expenditure then such a high rate of failure (9 in 10) warrants investigation. As one industry
commentator has observed “no other major business type operates under such a high failure
rate (> 90%) in the central, crucial process of the whole industrial drug discovery business. Fix
that and everything changes” (Lowe, 2019).

Over the past decade concerns have been raised over the fall off in new approval. Whilst the
much lauded 21-year high in approvals of NMEs in the US in 2017 and 2018 is welcome, such
approvals have still remained at low levels since the 2000s. (Takabe, 2018) with fewer novel
drugs (48) approved by the US Center for Drug Evaluation and Research in 2019 compared
with 59 in 2018 (Challener, 2020).

In 2018, the Congressional Budget Office (CBO, 2018) calculated that due to high failure rate,
biopharmaceutical companies would need to earn a 61.8 percent rate of return on their
successful new drug R&D projects in order to match a 4.8 percent after-tax rate of return on
their investments.
Kneller (Kneller, 2010) analysed the origins of 252 drugs that received FDA approval between
1998 and 2007. Up to 24% were transferred from universities to either biotechnology
companies (16%) or pharmaceutical companies (8%) showing that universities made a
substantial contribution to the discovery phase of innovative drugs over the period.
An analysis undertaken by the European Medicines Agency (EMA) (Lincker, 2014) of approvals
by the EMA over the period 2010-2012 noted that for innovative medicine in EU more than
40% of marketing authorisation originated from small or medium-sized enterprises (SMEs),
academia or public bodies and public-private partnerships. Of these 27% originate from SMEs
with 17% originating from academic institutions, public bodies and public-private
partnerships
3
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Whilst basic research in the context of pharmaceutical R&D, is a strength of academic
institutions, the ability to translate this research into a successful product is not necessarily
the forte or driver in the academic environment. The translation of research findings into
medicinal products suitable for use in the clinic requires detailed knowledge, skills and
facilities that are typically not located in academic setting (Hait, 2005, Bhavna Chawla, 2018).
Pharmaceutical companies have the resources to develop products complying with the
complex quality and manufacturing standards, whilst also compiling the regulatory dossiers
sufficient to meet requirements for regulatory submission and approvals (Starokozhko, 2020).
Furthermore there is an inherent conflict in that academic research is primarily measured and
valued by peer reviewed publications and success in obtaining grants (Frye, 2011). This leads
naturally to stronger interest in fundamental research rather than meeting the needs of the
industry (Huryn, 2013),

Although academic institutions as well as SMEs, public bodies and public-private partnerships
bolster the product pipelines of larger companies, academics are not typically seen to be
experts at bringing their product through the later stages of development and obtaining a
marketing authorization/ marketing approval. For many in the academic arena there is lack
of understanding of the specific regulatory requirements that are involved in drug
development and obtaining a successful approval.

In a European survey undertaken by the EMA (EMA, 2016) education on the role and activities
of regulators was highlighted as necessary in order to increase academia’s engagement in
regulatory science activities and research. The provision of education, training to academics
as well as the need for increased regulatory support were seen as important aids to help in
translating academic research into novel methodologies and medicinal products.

In the words of the EMA survey“understanding the factors that could affect drug innovation,
such as the nature of the organisations involved, could help in developing strategies to
catalyse further advances” (Lincker, 2014).
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There are initiatives being undertaken at a European level to bridge the gap between
academic researchers and their understanding of the regulatory pathway. The EMA have set
out their vision in their 2025 strategy (EMA, 2020a) with the aim to “catalyse and enable
regulatory science and innovation to be translated into patient access to medicines in evolving
healthcare systems”. In their planning the EMA seeks to help regulatory science develop and
use it to ensure that advances in knowledge translate in a timely way into new, safe and
effective treatments for patients.
In a 2018 study, Takebe et al investigated up to 800 drug discovery projects that took place
between 1991 and 2015 at 36 academic institutions in the United States and examined the
influence of industrial collaboration on the success rate of the academic projects. The authors
concluded what is needed is “closer industry-academia collaborations and integrated
computational– i.e. big data – experimental and clinical drug repurposing approaches are
needed to tackle the challenges and seize the opportunities in drug development”(Takabe,
2018). With the increasing awareness of pipeline stagnation, pharmaceutical companies
globally are turning their attention to universities conducting fundamental research in order
to acquire drug discovery “seeds” that originate in academia.

It has been established that the success rates for early development to successful launch is
less than 10%. The majority of these failures (75 to 80%) are mainly due to problems with
efficacy and/or safety (Dowden, 2019). Regulatory authorities have taken steps to mitigate
against these issues by the introduction of guidelines for the development of products. For
example the EMA have set up electronic guidance on their website in the section on clinical
efficacy and safety guidelines (EMA, 2020b). The aim of these guidelines are to help applicants
prepare marketing authorisation applications. The guidelines reflect a harmonised approach
of the EU Member States and the Agency on how to interpret and apply the requirements for
the demonstration of quality, safety and efficacy set out in the Community Directives and the
agency actively encourages applicants and marketing authorisation holders to follow these
guidelines. To further advance the supports the agency has introduced dedicated structures
to support human medicines R&D development and offers new platforms for engagement
with the academic world such as the establishment of innovation offices and scientific advice
services.
5
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As noted above there is a need to enhance the awareness of the role and activities of
regulators as a means to increase academia’s engagement in regulatory science activities and
research in order to translate academic research into novel methodologies and medicinal
products. It was identified that what is needed is for academics to have appropriate tools at
their disposal to allow them navigate the rigorous road of product development and the
stringent regulatory requirements, in short a regulatory tool to help identify where they are
in the process.
One tool already in use by academia is the Technology Readiness Levels (TRL) tool.The TRL
originated in NASA in the 70s, where it began as a means of measuring how far a technology
was from being deployed in space (Héder, 2017). The NASA researcher, Stan Sadin, conceived
the first scale in 1974. It had seven levels which were not formally defined until 1989. In
1990s NASA adopted a scale with nine levels which gained widespread acceptance across
industry and remains in use today (Olechowski, 2015). The US Department of Defense (DoD)
and the Commonwealth of Australia and NATO require the use of TRL in defence technology
acquisition. The usage of the TRL tool has spread among other governmental and military
organizations including the European Space Agency which in turn has led to its incorporation
in the EU Horizon 2020 programme and will also be used in its successor Horizon Europe 202127 (European Commission, 2020). In the EU the High-Level Expert Group on Key Enabling
Technologies (HLG-KET) built TRL into the foundation of its new public innovation policy (see
Figure 1). The universal usage of TRL in EU policy was proposed in the final report of the first
HLG-KET (HLG-KET, 2011).
The TRL model is a relatively simple model categorising the nine stages from basic research
to a proven deployment. The model is designed to be concise and easy to communicate. It
acts as a means to identify the stages that a technology is at and principally estimates the
maturity of that technology. Use of the tool to assess maturity of healthcare products, is
however somewhat limited, given that it was specifically designed for engineer-based
products. The US Army Medical Research and Materiel Command (AMRMC) have attempted
to address this and mapped the TRL descripts to the development of health care products (US
Department of Defense, 2009). A simplified TRL example for a therapeutic candidate would
progress through TRLs 1 to 4 involving basic technology research and preclinical studies,
cover clinical trial application (TRL5), to clinical trials (TRL6-8) and submissions for a product
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approval from the agencies (FDA or EMA) and then to product launch (TRL9) followed by
post-marketing studies and surveillance. It spans the whole innovation process, from basic
research activities to product launch and post-marketing activities. So whilst the AMRMC TRL
offers a useful tool to estimate the stage of development of a medicinal product, it is lacking
the degree of detail necessary to allow academic researchers to navigate the complex
regulatory routes to market. It does not contain the necessary granularity and depth that
covers the quality requirements for pharmaceutical products and the clinical guides needs for
bringing a product thought the complex development routes necessary for a successful
submission and ultimate approval. Most notably within the TRL level 4 to 7 (the development
stages that can be equated to “the Valley of Death” where initial research do not successfully
cross over to allow for a product to attain its commercial potential). It is claimed that this lack
of detail explains its relatively low uptake within the pharmaceutical and academic
development programmes (Webster, 2019).

An adaptation of the TRL approach which emphasises the detailed steps required on the
regulatory pathway would add substantially to the armoury of the researcher. An approach
would be to expand the TRL tool methodology to capture a pharmaceutical products
regulatory readiness. In doing so the regulatory gaps that prevent a pharmaceutical product
moving to the next stage are identified and the necessary remediation actions to be
implemented are indicated.

In a separate paper in this publication (O’Reilly, 2020), a survey of academic researchers and
relevant subject matter experts indicated there is a willingness among academic based
researchers to embrace a regulatory tool as part of their development strategies. In the study
the authors gauged the awareness and knowledge of academics and early stage researchers
in regards to the regulatory requirements to commercialise academic research and sought to
determine the interest in the use of a regulatory pathway tool (based on the TRL tool). It was
established that such researchers do not have the necessary training, knowledge, or
experience to enable them to engage in the regulatory pathways and there is a lack of clarity
around the regulatory requirements associated with commercialisation of basic scientific
research. It was identified that a simple, easy-to-use tool to guide early stage researchers
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along this regulatory pathway would be very useful. The introduction of such a tool would be
timely given the increased interest in academic settings to commercialise research.
This paper introduces a Regulatory Readiness Level (RRL) tool, developed by the author that
can confirm what stage of a process a technology is at and what are the steps needed to
complete the regulatory steps to advance development of the product and move to the next
TRL. This RRL tool can be used from early development work in academic laboratories to
commercial release (gauging the status /level the technology is currently at). The tool would
allow researchers to map to the next key stages whilst identifying the gaps and areas to focus
on and build strategies to reach RRL goals-milestones.

Early work conducted by the authors led to the creation of a simplified tool that outlines an
RRL based on a set of reached development milestones (see Figure 2). This tool also contained
9 levels (RRL 1 to 9) with an expansion of the TRL definitions to introduce scientific
requirements to be met at each of the regulatory readiness levels. This tool was subsequently
beta tested with a review group of industry based professional and an academic group
focussed on commercialisation of innovative products. Feedback on the tool was positive,
with constructive suggestions provided to enhance the workability and usefulness of this tool.
These included a further expansion of the RRL levels to give more detailed information on the
steps expected at each RRL and the introduction of an interactive element with provision of
hyperlinks to relevant regulatory agency guidance’s (e.g. Quality, Preclinical, Clinical and ICH
guidance).
The tool is now being further developed into a RRL model within a Microsoft Excel
programme, with the inclusion of series of questions (Yes/No) on the stage of development
allowing for an evaluation of the RRL level reached. An added functionality is included so that
where gaps in the RRL are identified, a mapping to suitable regulatory agency guidance is
available. As the same set of questions are answered each time in the tool, it provides
researchers a standardized, repeatable process for evaluating the status of a product under
development.

Conclusion
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The development of a medicinal product is a complex and time-consuming process with
numerous scientific, technical, and regulatory hurdles. Coupled with this is the increasing
costs associated with R&D, the reduction in product approvals and a shrinking pharmaceutical
industry pipeline. Academia has long been seen a source of innovative products that feed into
the pharmaceutical and biotechnology sectors. Whilst industry is well placed with to meet
the increasing challenge the academic arena struggles with this complex regulatory
environment and this is often cited as one of the barriers to translation of scientific research
to use in the clinical setting. It is now recognised that those is the academic sector have a
need for greater understanding of the regulatory requirements in place to achieve a
successful approval of a product.
The use of a Regulatory Readiness Level tool as envisaged by the authors will greatly facilitate
the increased awareness and advance the incorporation of regulatory science in the academic
sphere. The work on the further development, validation, and implementation of the RRL
tool in academic settings, followed by investigations into application and usefulness of the
RRL tool in a real-world setting in ongoing.
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FIGURE 1 - The TRL scale and EU HORIZON 2020 definitions
Standard TRL

HORIZON 2020 Definitions
TRL-6

TRL-1

Basic principles observed

Ideation

Initial scientific research has been conducted.
Principals are qualitatively postulated and
observed. Focus is on new discovery rather than
applications.

Early stage validation
(Continued)

TRL-2

Technology concept formulated

TRL-7

Proof of Principle

Initial practical applications are identified. Potential
of material, process to solve a problem, satisfy a
need or find application is confirmed

Late stage Validation

TRL-3

Experimental proof of concept
Applied research advances and early stage
development begins, Studies and laboratory
measurements validate analytical predictions of
separate elements of the technology
Technology validated in lab

TRL-8
Pre-commercialization

Proof of Concept
demonstrated
TRL-4
Proof of concept
established

TRL-5
Early stage
validation

Design, development and lab testing of
component/processes. Results provide evidence that
performance targets may be attainable based on
projected or modelled systems

TRL-9
Commercialization and
post market studies

Technology demonstrated in relevant
environment (industrially relevant
environment in the case of key enabling
technologies) System/process prototype
demonstration in an operational
environment (beta prototype)
System prototype demonstration in
operational environment
System/process prototype demonstration
in an operational environment (integrated
pilot system level)
System complete and qualified
Actual systems/process completed and
qualified though test and demonstration
(pre commercial demonstration)
Actual system proven in operational
environment (competitive manufacturing
in the case of key enabling technologies;
or in space)
Actual system proven through successful
operations in operating environment and
ready for full commercial deployment

Technology validated in relevant environment
(industrially relevant environment in the case of key
enabling technologies)
System component and/or process validation is
achieved in a relevant environment
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FIGURE 2 – Relationship between TRL and RRL scales.

TRL
TRL 1
TRL 2

TRL 3

•
•
•
•
•
•
•

TRL 4

•
•
•

TRL 5

•
•
•
•
•

TRL 6

•
•
•
•

TRL 7

•
•
•
•
•
•

TRL 8

•
•
•

TRL 9

•
•
•

Expansion of Activities
Scientific findings reviewed characterizing new technologies.

RRL Level
RRL 1

Generate research ideas “paper studies”
Developing research plans
Hypothesis are formed & identify candidate concepts &/or therapeutic drugs
Test hypothesis -evaluate technologies supporting drug development.
Initial synthesis of candidates, limited in-vitro and in-vivo research models initial proof of concept.
MOA & characterization of hits in preclinical studies

RRL 2.1 – 2.3

Demonstrate proof-of-concept & safety of candidate drug formulations
Preclinical studies (animal models) to assess potential safety & toxicity
problems, adverse events, & side effects.
Exploratory studies of hits/leads to set: formulation; routes of administration;
method of synthesis; physical & chemical properties; metabolic fate &
excretion/elimination; and dose ranging

RRL 4.1 –4.3

Non-clinical & pre-clinical research studies
Parametric data collection and analysis in well-defined systems.
Pilot lots drug candidate are produced for further development & provide the
basis for a manufacturing process tranferrable to cGMP-compliant pilot lot
production.
GLP safety & toxicity studies to evaluate PK/PD of candidate drugs.
Data package compiled of animal pharmacology & toxicology studies,
proposed manufacturing information, and clinical protocols for Phase 1
clinical testing.

RRL 5.1 –5.5

Phase 1 trial application submitted and approved
Phase 1 Clinicla Trial (CT) conducted
Production technologies demonstrated through production-scale cGMP plant
qualification.
PK & PD data to meet clinical safety requirements generated to support
design of Phase 2 CT l

RRL 6.1 – 6.4

Phase 2 CT conducted (initial efficacy & further safety, toxicity &
immunogenicity data.
Product final dose, dose range, schedule, & route of administration
established.
End of Phase 2 CT
Pre-Phase 3 meeting with agencies to discuss results of Phase /Phase 2 &
clinical endpoints and/or surrogate efficacy markers & test plans.
Phase 3 CT or surrogate test plan prepared
Application, & clinical protocol to support Phase 3 CT trials or surrogate
test plan submitted

RRL 7.1 – 7.5

Safety & effectiveness in Phase 3 CT or surrogate tests.
Evaluate overall risk-benefit of administering candidate product & provide
basis for drug labelling.
Process validation completed, followed by lot consistency and
reproducibility studies.
Dossier prepared & submitted to agency
Approval Received
Product launch and monitoring in the market.

RRL 8.1 – 8.3

RRL 3.1 – 3.3

RRL 9.1 – 9.2

15
Published by ARROW@TU Dublin, 2020

15

Level 3, Vol. 15, Iss. 2 [2020], Art. 6
Level3

Issue 17, December 2020

Technological University Dublin

16
https://arrow.tudublin.ie/level3/vol15/iss2/6
DOI: https://doi.org/10.21427/qp14-dy42

16

